Should PNV consider taking over ARX?, page-5

  1. 244 Posts.
    lightbulb Created with Sketch. 35
    There is room for both biological and synthetic products in the market.
    Patients/ medical experts already have a choice between the two, and there are many patients where biological products may be more suitable.
    Why not have a product portfolio that offer both types of products.
    The forecast revenue of ARX is not that far behind PNV for the next few years, proving that there is a market for biological products.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.17
Change
-0.055(4.51%)
Mkt cap ! $815.1M
Open High Low Value Volume
$1.23 $1.23 $1.17 $2.186M 1.841M

Buyers (Bids)

No. Vol. Price($)
14 32723 $1.17
 

Sellers (Offers)

Price($) Vol. No.
$1.17 94061 51
View Market Depth
Last trade - 14.30pm 07/07/2025 (20 minute delay) ?
PNV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.